ABUS vs CSX · P/E 5.4, rev $6.2M vs P/E 19, rev $14.09B
Arbutus Biopharma Corp (ABUS) versus CSX Corporation (CSX) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
CSX Corporation (CSX) is a railroads company listed on US.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported CSX revenue for 2025-12-31 was $14.09B. Net income was $2.89B. Revenue was down 3.1% from 2024-12-31 to 2025-12-31. CSX currently screens at market cap $61.18B and trailing P/E 19.4.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. CSX currently screens at market cap $61.18B and trailing P/E 19.4.
Not investment advice. Open the ABUS and CSX stock pages for the full models.
Not investment advice.